StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences other HIV products (incl. Sunlenca & Yeztugo prior to Q1 2026) ($M) ($M)

Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary

QuarterlyAnnual
Latest, Q2 2026
56
Period ended Jun 30, 2026
Change on a year earlier
-39.1%
92 in Q2 2025
History
37 quarters
Since Q2 2017
Sources
29
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther HIV products (incl. Sunlenca & Yeztugo prior to Q1 2026) ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202656-39.1%Form 10-Q (filed 2026-08-06) ↗
Q1 2026Mar 31, 202673-19.8%Form 10-Q (filed 2026-05-07) ↗
Q4 2025Dec 31, 2025190+69.6%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 2025112+12.0%Form 10-Q (filed 2025-11-07) ↗
Q2 2025Jun 30, 202592-12.4%Form 10-Q (filed 2026-08-06) ↗
Q1 2025Mar 31, 202591-22.2%Form 10-Q (filed 2026-05-07) ↗
Q4 2024Dec 31, 2024112+40.0%Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 2024100+6.4%Form 10-Q (filed 2025-11-07) ↗
Q2 2024Jun 30, 2024105-12.5%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 2024117+8.3%Form 10-Q (filed 2025-05-07) ↗
Q4 2023Dec 31, 202380-83.5%Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 202394+683.3%Form 10-Q (filed 2024-11-12) ↗
Q2 2023Jun 30, 2023120+566.7%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023108+671.4%Form 10-Q (filed 2024-05-08) ↗
Q4 2022Dec 31, 2022485+1,054.8%Form 10-K (filed 2025-02-28) ↗
Q3 2022Sep 30, 202212-64.7%Form 10-Q (filed 2023-11-07) ↗

Breakdown

What makes up other hiv products (incl. sunlenca & yeztugo prior to q1 2026) ($m)

Cite this data

StockData. (2026). Gilead Sciences Other HIV products (incl. Sunlenca & Yeztugo prior to Q1 2026) ($M) ($M), quarterly Q2 2017–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/hiv_other

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.